Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases
Top Cited Papers
Open Access
- 1 May 2017
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 3 (5), 666-671
- https://doi.org/10.1001/jamaoncol.2016.5630
Abstract
Brain metastases (BrM) occur in 10% to 15% of patients with metastatic breast cancer (BrCa) and present a major clinical challenge, highlighted by a poor 8.5-month median overall survival.1 Limited therapeutic options exist for patients with BrM and current management consists of surgical resection, radiation therapy, and chemotherapy. ERBB2/HER2-positive BrM have demonstrated encouraging responses to ERBB2/HER2-targeted therapies in recent clinical trials.2 Unfortunately, in patients with ERBB2/HER2-negative BrM, no targeted therapies have shown even modest benefits.3Keywords
This publication has 15 references indexed in Scilit:
- CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA SequencingPLoS Computational Biology, 2016
- Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomesBritish Journal of Cancer, 2016
- DGIdb 2.0: mining clinically relevant drug–gene interactionsNucleic Acids Research, 2015
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic TargetsCancer Discovery, 2015
- Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2014
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast CancerCancer Discovery, 2013
- Copynumber: Efficient algorithms for single- and multi-track copy number segmentationBMC Genomics, 2012
- Changes in Keratin Expression during Metastatic Progression of Breast Cancer: Impact on the Detection of Circulating Tumor CellsClinical Cancer Research, 2012
- Keratins in health and cancer: more than mere epithelial cell markersOncogene, 2010
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010